Ozempic (Semaglutide) and Pregnancy: What the Evidence Says About Safety During Conception, Pregnancy, and Breastfeeding

FDA Labeling and Regulatory Classification

The FDA prescribing information for Ozempic explicitly states that semaglutide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [1]. No human controlled trials have evaluated semaglutide in pregnant patients. This classification rests almost entirely on preclinical animal data and the pharmacological properties of the GLP-1 receptor agonist class.

Novo Nordisk's label recommends discontinuing Ozempic at least 2 months before a planned pregnancy, a timeline derived from the drug's prolonged half-life of approximately 168 hours (7 days) [1]. At that half-life, 2 months provides roughly 8 to 9 elimination half-lives, reducing circulating drug to negligible concentrations. The FDA's clinical pharmacology review for the original 2017 approval confirmed this pharmacokinetic profile across subcutaneous doses of 0.5 mg and 1.0 mg [2]. Patients who become pregnant while on Ozempic should contact their prescriber immediately. Novo Nordisk also maintains a pregnancy exposure registry to monitor outcomes in women inadvertently exposed during gestation [1].

How Semaglutide Works and Why That Matters for Pregnancy

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone glucagon-like peptide-1 by binding to GLP-1 receptors on pancreatic beta cells, amplifying glucose-dependent insulin secretion and suppressing glucagon release [3]. The drug also slows gastric emptying and acts on hypothalamic appetite centers to reduce caloric intake.

These mechanisms raise specific concerns in pregnancy. Slowed gastric motility may worsen nausea and vomiting, which are already prevalent during the first trimester. Reduced caloric intake and appetite suppression can limit the nutrient delivery that is critical during organogenesis and fetal growth. GLP-1 receptors are expressed in multiple fetal tissues in animal models, though the functional significance of fetal receptor activation in humans remains unclear [4]. The combination of prolonged half-life, potent appetite suppression, and widespread receptor expression makes the precautionary principle especially relevant for this drug class.

Animal Reproductive Toxicology Data

The preclinical evidence is the primary basis for the pregnancy warning. It is not reassuring.

In rat embryofetal development studies, subcutaneous semaglutide administered during organogenesis caused structural abnormalities including skeletal and visceral malformations at doses producing exposures approximately 0.5 to 5 times human clinical exposure at the maximum recommended dose of 1.0 mg weekly, based on area-under-the-curve (AUC) comparisons [1]. Findings included early embryonic deaths, reduced fetal weight, and delayed ossification. Rabbit studies showed similar dose-dependent embryolethality and fetal growth restriction at clinically relevant AUC multiples [1].

A key detail: these adverse outcomes occurred at exposure levels that overlap with or are close to therapeutic human exposures. That contrasts with many drugs where animal toxicity only appears at exposures many times higher than human doses. The European Medicines Agency's assessment report for Ozempic noted that the margin between the no-observed-adverse-effect level (NOAEL) for embryofetal toxicity and human therapeutic exposure was narrow [5].

In a pre- and postnatal development study in rats, semaglutide exposure during gestation and lactation reduced pup survival and body weight at maternally toxic doses [1]. Whether these effects were direct fetal/neonatal toxicity or secondary to maternal toxicity (reduced food intake, weight loss) could not be fully separated.

Human Data: What We Know and What We Don't

No randomized controlled trials have enrolled pregnant patients taking semaglutide. Current human evidence comes from three sources: inadvertent pregnancy exposures reported during clinical trials, post-marketing pharmacovigilance databases, and registry data.

A 2024 cohort analysis using Nordic health registries examined pregnancy outcomes in women exposed to GLP-1 receptor agonists (including semaglutide and liraglutide) during early pregnancy [6]. The study found no statistically significant increase in major congenital malformations compared to unexposed diabetic pregnancies, though the sample size was small (fewer than 500 exposed pregnancies across all GLP-1 RAs), and the confidence intervals were wide. The authors cautioned that the data were insufficient to rule out a modest increase in risk.

The CDC's treating-for-two initiative tracks medication exposures during pregnancy but has not published semaglutide-specific outcome data as of early 2026 [7]. The Novo Nordisk pregnancy registry continues to enroll participants, though results have not yet been published in peer-reviewed form.

An important distinction: absence of evidence is not evidence of absence. The lack of a clear human teratogenic signal may reflect limited exposure data rather than true safety. The American College of Obstetricians and Gynecologists (ACOG) has not issued a specific guidance document on GLP-1 RA use in pregnancy, but general ACOG guidance recommends avoiding medications without established human pregnancy safety data when safer alternatives exist [8].

The Washout Period: Two Months Is a Minimum

The 2-month washout recommendation is pharmacokinetically grounded. Semaglutide's half-life of approximately 7 days means that after a single dose, it takes about 5 weeks (5 half-lives) for the drug to fall below 3% of peak concentration. Eight to 9 half-lives, or 56 to 63 days, reduces residual drug to less than 0.5% of peak levels [2].

Patients stopping Ozempic before conception should understand several practical points. First, fertility may increase as weight decreases. Women with polycystic ovary syndrome (PCOS) or obesity-related anovulation may resume ovulating during or shortly after semaglutide treatment, sometimes before the washout period is complete [9]. This creates a window for unplanned pregnancy with residual drug exposure. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy explicitly warns that "women of reproductive potential should use effective contraception during treatment with anti-obesity medications and for a period after discontinuation" [10].

Second, the washout applies to all semaglutide formulations, not just Ozempic. Patients switching from Wegovy (semaglutide 2.4 mg) to a conception attempt need the same 2-month minimum, and the higher dose does not substantially change the washout math because the half-life is dose-independent [2].

Third, glucose control must be maintained during the transition. For patients with type 2 diabetes, stopping semaglutide without a replacement strategy risks hyperglycemia, which itself carries teratogenic risk. Preconception HbA1c targets of <6.5% are associated with reduced congenital malformation rates, as established in the ADA Standards of Care [11].

Glucose Management Alternatives During Pregnancy

Insulin is the gold standard for managing hyperglycemia in pregnancy. Both the ADA and ACOG endorse insulin as first-line pharmacotherapy for type 2 diabetes during gestation because it does not cross the placenta in clinically significant amounts [11][8].

Metformin is sometimes used as an adjunct or alternative, particularly in patients who cannot manage insulin therapy. The MiG trial (Metformin in Gestational Diabetes) demonstrated that metformin was not associated with increased perinatal complications compared to insulin, though it does cross the placenta, and long-term offspring follow-up data remain limited [12]. Glyburide, once commonly used, has fallen out of favor after meta-analyses showed higher rates of neonatal hypoglycemia and macrosomia compared to insulin [13].

For patients using Ozempic primarily for weight management (off-label at 0.5 to 1.0 mg or via Wegovy at 2.4 mg), no pharmacological weight-loss agent is approved for use in pregnancy. Weight management during pregnancy shifts to nutritional counseling, activity modification, and gestational weight gain targets based on pre-pregnancy BMI, as outlined by the Institute of Medicine guidelines [14].

Semaglutide and Breastfeeding

The lactation data are sparse. Semaglutide was detected in the milk of lactating rats, but no human lactation studies have been performed [1]. Given the drug's molecular weight (approximately 4,114 Da) and high protein binding (>99%), some pharmacologists predict limited transfer into breast milk, but this remains theoretical.

The NIH LactMed database, a standard reference for drug safety during breastfeeding, lists GLP-1 receptor agonists as having insufficient data to recommend use during lactation [15]. The large peptide structure of semaglutide suggests it may be partially degraded in the infant's gastrointestinal tract, but oral bioavailability is not zero (Rybelsus, the oral semaglutide formulation, demonstrates this), and neonatal gut permeability differs from adult gut permeability.

A practical concern: semaglutide's appetite-suppressing effects could theoretically reduce maternal caloric intake during a period when breastfeeding women require an additional 450 to 500 kcal per day [16]. Caloric restriction during lactation can reduce milk supply and compromise milk fat content. For these reasons, most endocrinologists and OB-GYNs advise against resuming semaglutide until breastfeeding is complete.

Fertility Considerations: The "Ozempic Baby" Phenomenon

Popular media has reported a surge in unplanned pregnancies among women taking GLP-1 receptor agonists, often called "Ozempic babies." The biological plausibility is real. Weight loss of 5% to 10% of body weight can restore ovulatory cycles in women with PCOS or obesity-related anovulation [9]. Since semaglutide 1.0 mg produces mean weight loss of 5.5 to 7.3 kg over 40 weeks in patients with type 2 diabetes (SUSTAIN-7, N=1,199) [17], and higher doses produce greater weight loss, fertility restoration is a predictable pharmacological consequence.

Oral contraceptive efficacy may also be affected. Semaglutide slows gastric emptying, which can alter the absorption kinetics of co-administered oral medications [1]. The Ozempic label notes that semaglutide did not affect the overall exposure of oral contraceptives containing ethinylestradiol and levonorgestrel to a clinically relevant degree in a dedicated drug-interaction study, but the peak concentration (Cmax) of ethinylestradiol was reduced by 33% [2]. Whether this Cmax reduction has clinical relevance for contraceptive failure rates is unknown. Prescribers should discuss barrier methods or non-oral contraceptives (IUDs, implants, injections) with patients on semaglutide who wish to avoid pregnancy.

What to Do If You Become Pregnant While on Ozempic

Stop the medication and contact your prescriber. This is not a situation that warrants waiting until the next scheduled appointment. The steps are straightforward:

1. Discontinue Ozempic immediately.
2. Contact your endocrinologist or prescribing clinician the same day.
3. Schedule an early obstetric ultrasound to confirm viability and gestational age.
4. Transition glucose management to insulin if indicated for type 2 diabetes.
5. Report the exposure to the Novo Nordisk pregnancy registry at 1-800-727-6500.
6. Discuss the exposure with a maternal-fetal medicine specialist, particularly if exposure occurred during organogenesis (weeks 3 through 8 post-conception).

The timing of exposure matters. First-trimester exposure during organogenesis carries the highest theoretical risk based on the animal data. Exposure limited to the periconceptional period (before implantation) is generally considered lower risk, though data specific to semaglutide are lacking.

Preconception Planning for Patients on Semaglutide

A structured preconception plan reduces risk. The ADA recommends that women with type 2 diabetes achieve an HbA1c of <6.5% before conception, using pregnancy-compatible medications [11]. For a patient currently on Ozempic, the transition typically follows this sequence:

Start reliable contraception if not already in use. Optimize HbA1c to target using current therapy. Begin insulin titration while still on semaglutide so that glycemic control is stable before the switch. Discontinue semaglutide. Maintain contraception for at least 2 months after the last injection. Confirm HbA1c remains at target on the insulin-based regimen. Then attempt conception.

For patients using semaglutide off-label for weight management without diabetes, the transition is simpler: discontinue, wait 2 months, confirm no residual metabolic concerns, and proceed. Weight regain after discontinuation is common. The STEP-1 extension data showed that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide 2.4 mg [18]. Patients should be counseled that some weight regain during the washout and pregnancy is expected and physiologically normal.

Folic acid supplementation (400 to 800 mcg daily) should begin at least one month before conception and continue through the first trimester, consistent with USPSTF recommendations, regardless of prior medication exposure [19].